693 related articles for article (PubMed ID: 28510338)
1. Therapeutic Targeting of Poly(ADP-Ribose) Polymerase-1 (PARP1) in Cancer: Current Developments, Therapeutic Strategies, and Future Opportunities.
Rajawat J; Shukla N; Mishra DP
Med Res Rev; 2017 Nov; 37(6):1461-1491. PubMed ID: 28510338
[TBL] [Abstract][Full Text] [Related]
2. The development of PARP as a successful target for cancer therapy.
Ferrara R; Simionato F; Ciccarese C; Grego E; Cingarlini S; Iacovelli R; Bria E; Tortora G; Melisi D
Expert Rev Anticancer Ther; 2018 Feb; 18(2):161-175. PubMed ID: 29260919
[TBL] [Abstract][Full Text] [Related]
3. EZH2 contributes to the response to PARP inhibitors through its PARP-mediated poly-ADP ribosylation in breast cancer.
Yamaguchi H; Du Y; Nakai K; Ding M; Chang SS; Hsu JL; Yao J; Wei Y; Nie L; Jiao S; Chang WC; Chen CH; Yu Y; Hortobagyi GN; Hung MC
Oncogene; 2018 Jan; 37(2):208-217. PubMed ID: 28925391
[TBL] [Abstract][Full Text] [Related]
4. Expression and Single Nucleotide Polymorphism of Poly (ADPRibose) Polymerase-1 in Gastrointestinal Tumours: Clinical Involvement.
Martín-Guerrero SM; León J; Quiles-Perez R; Belmonte L; Martin-Oliva D; Ruiz-Extremera Á; Salmerón J; Muñoz-Gámez JA
Curr Med Chem; 2017; 24(20):2156-2173. PubMed ID: 28302009
[TBL] [Abstract][Full Text] [Related]
5. An Update on Poly(ADP-ribose)polymerase-1 (PARP-1) Inhibitors: Opportunities and Challenges in Cancer Therapy.
Wang YQ; Wang PY; Wang YT; Yang GF; Zhang A; Miao ZH
J Med Chem; 2016 Nov; 59(21):9575-9598. PubMed ID: 27416328
[TBL] [Abstract][Full Text] [Related]
6. Poly (ADP-ribose) polymerase-1 as a promising drug target for neurodegenerative diseases.
Thapa K; Khan H; Sharma U; Grewal AK; Singh TG
Life Sci; 2021 Feb; 267():118975. PubMed ID: 33387580
[TBL] [Abstract][Full Text] [Related]
7. Studying PAR-Dependent Chromatin Remodeling to Tackle PARPi Resistance.
Andronikou C; Rottenberg S
Trends Mol Med; 2021 Jul; 27(7):630-642. PubMed ID: 34030964
[TBL] [Abstract][Full Text] [Related]
8. PARP Inhibitors in Cancer Diagnosis and Therapy.
Chan CY; Tan KV; Cornelissen B
Clin Cancer Res; 2021 Mar; 27(6):1585-1594. PubMed ID: 33082213
[TBL] [Abstract][Full Text] [Related]
9. Medicinal chemistry approaches of poly ADP-Ribose polymerase 1 (PARP1) inhibitors as anticancer agents - A recent update.
Jain PG; Patel BD
Eur J Med Chem; 2019 Mar; 165():198-215. PubMed ID: 30684797
[TBL] [Abstract][Full Text] [Related]
10. DNA Damage Repair and the Emerging Role of Poly(ADP-ribose) Polymerase Inhibition in Cancer Therapeutics.
Rabenau K; Hofstatter E
Clin Ther; 2016 Jul; 38(7):1577-88. PubMed ID: 27368114
[TBL] [Abstract][Full Text] [Related]
11. PARP1 roles in DNA repair and DNA replication: The basi(c)s of PARP inhibitor efficacy and resistance.
Kanev PB; Atemin A; Stoynov S; Aleksandrov R
Semin Oncol; 2024; 51(1-2):2-18. PubMed ID: 37714792
[TBL] [Abstract][Full Text] [Related]
12. Poly(ADP-Ribose) polymerase 1: a therapeutic hope in gynecologic cancers.
Rajawat J; Shukla N; Mishra DP
Front Biosci (Schol Ed); 2017 Jun; 9(3):343-356. PubMed ID: 28410123
[TBL] [Abstract][Full Text] [Related]
13. Poly(ADP-ribose) polymerase inhibitor therapeutic effect: are we just scratching the surface?
Hottiger MO
Expert Opin Ther Targets; 2015; 19(9):1149-52. PubMed ID: 26212149
[TBL] [Abstract][Full Text] [Related]
14. Poly(ADP-ribose) polymerase inhibitors activate the p53 signaling pathway in neural stem/progenitor cells.
Okuda A; Kurokawa S; Takehashi M; Maeda A; Fukuda K; Kubo Y; Nogusa H; Takatani-Nakase T; Okuda S; Ueda K; Tanaka S
BMC Neurosci; 2017 Jan; 18(1):14. PubMed ID: 28095779
[TBL] [Abstract][Full Text] [Related]
15. New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors.
Liu FW; Tewari KS
Curr Treat Options Oncol; 2016 Mar; 17(3):12. PubMed ID: 26931795
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms of PARP inhibitor sensitivity and resistance.
D'Andrea AD
DNA Repair (Amst); 2018 Nov; 71():172-176. PubMed ID: 30177437
[TBL] [Abstract][Full Text] [Related]
17. Targeting PARP proteins in acute leukemia: DNA damage response inhibition and therapeutic strategies.
Padella A; Ghelli Luserna Di Rorà A; Marconi G; Ghetti M; Martinelli G; Simonetti G
J Hematol Oncol; 2022 Jan; 15(1):10. PubMed ID: 35065680
[TBL] [Abstract][Full Text] [Related]
18. PARP-1-Associated Pathological Processes: Inhibition by Natural Polyphenols.
Maluchenko NV; Feofanov AV; Studitsky VM
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34768872
[TBL] [Abstract][Full Text] [Related]
19. PARP inhibitor resistance: the underlying mechanisms and clinical implications.
Li H; Liu ZY; Wu N; Chen YC; Cheng Q; Wang J
Mol Cancer; 2020 Jun; 19(1):107. PubMed ID: 32563252
[TBL] [Abstract][Full Text] [Related]
20. [From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].
Schreiber V; Illuzzi G; Héberlé E; Dantzer F
Bull Cancer; 2015 Oct; 102(10):863-73. PubMed ID: 26384693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
